The growing number of approvals from the Food and Drug Administration (FDA) drives the growth of the melanoma cancer market

The global melanoma cancer market is anticipated to grow at a CAGR of around 12.3% during the forecast period (2021-2027). The factor propelling the growth of the market include the rise in the number of FDA approvals for melanoma cancer drugs/systems produced by key market players. For instance, in July 2021, Genentech, a subsidiary of F. Hoffmann-La Roche Ltd, got the approval for Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib). These drugs are used for the treatment of BRAF V600 mutation-positive advanced melanoma. The FDA approval is supported by results from the Phase 3 IMspire150 clinical trial done on peoples who suffered from advanced melanoma and previously untreated BRAF V600 mutation. The approval will support Roche to build a strong market for the Tecentriq/Cotellic combo.

Browse the full report description of "Global Melanoma Cancer Market Size, Share & Trends Analysis Report By Diagnosis (Biopsy, Computed Tomography (CAT) Scan, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) Scan), By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Radiation therapy), Forecast 2021-2027" at https://www.omrglobal.com/industry-reports/melanoma-cancer-market

Moreover, in May 2020, SciBase, announced that it has received approval from the FDA for Nevisense 3.0, the third generation of their Nevisense system for early melanoma detection. Nevisence is an AI-based point-of-care system that is used for the non-invasive evaluation of irregular moles. Through this approval for the system to detect early melanoma cancer will support the company to expand its marketing and sales activities in the market. Thus, these approvals by FDA will impact positively the growth of the melanoma cancer market during the forecast period.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Diagnosis

o By Therapy

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Bristol-Myers Squibb Co., GlaxoSmithKline plc, AstraZeneca PLC, Amgen Inc, Novartis AG, Abbott Laboratories, Johnson & Johnson Services, Inc., and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Melanoma Cancer Market Segmentation

By Diagnosis 

• Biopsy
• Computed Tomography (CAT) Scan
• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET) Scan

By Therapy

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy

Global Melanoma Cancer Market Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa

To learn more about this report request a sample copy @  https://www.omrglobal.com/request-sample/melanoma-cancer-market